by Prakash Achaary | Mar 24, 2022 | Blog
Part 1: Medical Writing and Pharmacovigilance We sat down with the instructors for MMS Academy, MMS’ learning arm, for some advice on how to be successful to help those looking to work in the pharma industry. In this first article, we talked with our instructors for...
by Prakash Achaary | Mar 17, 2022 | Blog
The Orphan Drug Act provides incentives to sponsors to promote the development of drugs for the prevention, diagnoses, and treatment of rare diseases or conditions that affect fewer than 200,000 individuals in the United States, and for which the sponsor is not...
by Prakash Achaary | Feb 3, 2022 | News
CANTON, Mich. (3/10/2022) – MMS Holdings, a data-focused contract research organization (CRO), announced the addition of Robert Allen, MD, as Principal Medical Director of Global Drug Safety and Pharmacovigilance to its team. Bringing more than 20 years of...
by Prakash Achaary | Feb 2, 2022 | News
CANTON, Mich. (2/2/2022) – MMS Holdings, a data-focused clinical research organization, was recognized in the 2022 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates. MMS, a minority...
by Prakash Achaary | Jan 24, 2022 | Blog
In September 2021, the Food and Drug Administration (FDA) released its Benefit-Risk Assessment Guidance as part of the Prescription Drug User Fee Amendments (PDUFA) VI Implementation Plan which covers 2018 through 2022. PDUFA VI focuses on integrating patient...